Shilpa Medicare partners for innovative cancer therapy development

Shilpa Medicare’s subsidiary, Shilpa Biologicals, has partnered with Swiss firm mAbTree Biologics to develop a new cancer therapy. Shilpa will manage the drug's development and manufacturing at its facility in Karnataka. The therapy is a fully human monoclonal antibody targeting a new immune checkpoint protein. It aims to improve T-cell activation and may help treat various cancers by converting 'cold' tumors into 'hot' tumors. This collaboration seeks to enhance access to innovative cancer treatments in India and other markets. Shilpa Medicare's stock rose slightly, despite a 23 percent decline since the beginning of the year.